# The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

> **NCT05322031** · PHASE4 · COMPLETED · sponsor: **Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico** · enrollment: 15 (actual)

## Conditions studied

- Schizophrenia
- Myelin Degeneration
- Cognition Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT05322031
- **Lead sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-11-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322031, "The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05322031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*